Renal cell carcinoma (RCC) affects over 400,000 patients globally each year, and 30% of patients present with metastatic disease. Current standard of care therapy for metastatic RCC involve TKIs and ICIs, including combinatorial strategies, but this offers only modest clinical benefit. Novel treatment approaches are warranted, and cell-based immunotherapies for RCC hold significant promise. These are currently being tested in the pre-clinical setting and in early phase clinical trials. Here, we review the landscape of cellular immunotherapy for RCC in the context of currently available therapies, with a particular focus on defining the current best antigenic targets, the range of cell therapy products being explored in RCC, and how advanced engineering solutions may further enhance these therapies in the RCC space.
Cancers. 2024 Mar 19*** epublish ***
Angela Hwang, Vedika Mehra, Jyoti Chhetri, Samira Ali, Maxine Tran, Claire Roddie
Department of Haematology, University College Hospital, University College London Hospitals NHS Foundation Trust, London NW1 2BU, UK., University College London Cancer Institute, 72 Huntley Street, London WC1E 6DD, UK., University College London Division of Surgery and Interventional Science, Rowland Street, London NW3 2QG, UK.